查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年心律失常监测设备的全球市场
市场调查报告书
商品编码
1217636

2023-2030 年心律失常监测设备的全球市场

Global Cardiac Arrhythmia Monitoring Devices Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

心律失常监测是一种用于确定不规则心率或心律的原因或类型的测试。 心律失常监测设备是用来监测和监测心率的设备。 开发了许多用于监测心律的产品，例如 Holter 监测器、移动心臟遥测和 ECG 设备。

市场动态

推动全球心律失常监测设备市场的主要因素是，由于心血管疾病的发病率不断增加，需要持续监测以获得更好的治疗，因此对智能心臟监测设备的需求不断增长；导致意识激增和新产品发布的技术进步.

智能心臟监护仪新兴市场的开发以及对远程心脏病学不断增长的需求预计将推动市场增长。

心律失常监测设备市场受到远程心脏病学需求增加、技术进步不断增加、老年人口不断增加、研发投资激增、慢性心脏病数量增加以及新兴市场医疗保健基础设施不断改善的推动。使用最新技术改进产品。

心律失常监测设备广泛用于持续监测心律和适当管理医疗状况。 随着这些设备越来越受欢迎，政府的承诺和资金也越来越多。 这些资金将用于生产更先进的产品，例如用于监测的智能心臟监护仪和智能手錶。 由于患有心血管疾病的人数不断增加，这些心律失常监测设备的市场在全球范围内不断扩大。 此外，预计主要参与者提供的技术先进的产品也将在市场增长中发挥重要作用。

与这些心律失常监测设备相关的各种新产品发布、研究和提高认识活动正在促进市场的增长。 例如，2021 年 5 月 24 日，专注于推进心臟护理的数字医疗解决方案公司 iRhythm Technologies, Inc. 宣布了两项新的 510(k) 许可。 一个是具有更好设计的新旗舰显示器，另一个是改进的人工智能 (AI) 功能。 新的 Zio 监视器的开发旨在提高患者的舒适度，增强的 AI 功能可进一步提高心跳和节律的诊断准确性。

不确定的报销政策预计会阻碍市场增长。

然而，与这些心臟监测设备相关的不确定报销政策可能是阻碍市场增长的关键因素。 由于这种不确定性，临床医生和患者都对采用这些监测设备犹豫不决。

此外，关于批准这些用于监测心血管疾病和医疗状况的设备的严格规则和法规也阻碍了心律失常监测设备市场的增长。 智能心臟监护仪和智能手錶等高级监护仪的高成本也可能限制市场增长。

COVID-19 影响分析

疫情对全球金融预期、运营和危机应对策略产生了负面影响。 COVID-19 的爆发严重影响了医疗保健行业。 由于 COVID，心律失常监测设备市场遭受了巨大损失。 主要製造商已经启动了各种研究和临床试验。 世界各地正在开展各种举措、产品发布、合作和合併，以促进市场的增长。 例如，2022 年 7 月 22 日，专注于推进心臟护理的数字医疗保健解决方案公司 iRhythm Technologies, Inc. 将获得 USFDA 对 Zio Watch 的 ZEUS 系统（Zio ECG Utilization Software）的许可。宣布关于 该系统是与精准医疗公司 Verily 合作开发的。 ZEUS 系统将值得信赖的心律失常服务与深度学习算法相结合。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 增加智能心电图仪的开发
      • 对远程心脏病学（远程心臟诊断）的需求增加
    • 约束因素
      • 赎回政策不明确
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章副产品

  • 动态心电监护仪
  • 心电图设备
  • 移动心臟遥测
  • 心臟事件监测器
  • 植入式循环记录仪
  • 补丁监视器
  • 起搏器
  • 心律转復除颤器

第八章应用

  • 房颤
  • 心动过缓
  • 房性心动过速
  • 室性心动过速
  • 心室颤动
  • 早产
  • 其他

第 9 章最终用户

  • 医院
  • 门诊手术中心
  • 诊断中心
  • 专科诊所

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第12章公司简介

  • 飞利浦医疗
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • GE Healthcare
  • Medtronic PLC
  • Cardiac Sense
  • BIOTRONIK
  • iRhythm Technologies, Inc.
  • Preventice Solutions（Boston Scientific Corporation）
  • Medi-Lynx Cardiac Monitoring LLC.
  • ACS Diagnostics
  • Abbott

第13章 DataM

简介目录
Product Code: DMMD1281

Market Overview

The global cardiac arrhythmia monitoring devices market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

Cardiac arrhythmia monitoring is a kind of test utilized to determine the cause and type of the irregular heart rates or heart rhythms. The devices utilized to monitor or observe the heart rates are the cardiac arrhythmia monitoring devices. There are numerous products developed for monitoring the heart rhythms including holter monitor, mobile cardiac telemetry or ECG devices.

Market Dynamics

The major factors driving the global cardiac arrhythmia monitoring devices market are the rising demand for smart cardiac monitoring devices owing to increasing incidences of cardiovascular disorders requiring continuous monitoring for better treatment, surging awareness initiatives, advancements in technologies leading to novel product launches.

The increasing development of smart cardiac monitors and rising demand for telecardiology are expected to drive the market's growth.

The cardiac arrhythmia monitoring devices market is driven by increasing demand of telecardiology, rising advancements in technology, an increase in the geriatric population, a surge in research and development investments, an increasing number of chronic cardiovascular diseases and improvements in novel products using the latest technology along with improvements in medical infrastructure in emerging markets.

The cardiac arrhythmia monitoring devices are used widely for continuous monitoring of rhythms of heart for management of the condition properly. The adoption of these devices is increasing, leading to rising government initiatives and funds. These funds will help produce more developed products such as smart cardiac monitors or smart watches for monitoring. The market for these cardiac arrhythmia monitoring devices is increasing worldwide due to the enhanced number of people suffering from cardiovascular disorders. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, research studies, and rising awareness initiatives related to these cardiac arrhythmia monitoring devices contribute to the market's growth. For instance, in May 24, 2021, iRhythm Technologies, Inc., a company of digital healthcare solutions focused on cardiac care advancement announced two novel 510(k) clearances. One for a novel flagship monitors with better design and second for an improved artificial intelligence (AI) capabilities. The novel Zio monitor is developed to enhance patient comfort while its AI capabilities advancements will further improve beat and rhythm diagnostic accuracy.

Uncertain reimbursement policies are expected to hamper the market's growth.

However uncertain reimbursement policies associated with these cardiac monitoring devices is the key factor which may hamper the market growth. Due to the uncertainty clinicians as well as patients hesitate in adopting these monitoring devices.

The strict rules and regulations for the approval of these devices utilized for monitoring of cardiovascular disorders or conditions is also a factor hindering the growth of the cardiac arrhythmia monitoring devices market. High costs of highly advanced monitors such as smart cardiac monitors or smart watches can also limit the growth of the market.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The cardiac arrhythmia monitoring devices market has experienced huge losses due to COVID. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, July 22, 2022, iRhythm Technologies, Inc., a company of digital healthcare solutions focused on cardiac care advancement announced about receiving clearance for Zio Watch's ZEUS System (Zio ECG Utilization Software) by USFDA. This system is developed in partnership with Verily, a precision health company. ZEUS System combines trusted cardiac arrhythmia service with deep learned algorithms.

Segment Analysis

The holter monitors segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

The holter monitor segment is the highest market holder in the global cardiac arrhythmia monitoring devices market. The global cardiac arrhythmia monitoring devices market is segmented based on product as holter monitors, ECG devices, mobile cardiac telemetry, cardiac event monitors, implantable loop recorders, patch monitor, pacemaker, cardioverter-defibrillator. The holter monitors segment is the largest market shareholder due to the increasing adoption of these devices globally for monitoring, increasing technological advancements and novel product launches.

Holter monitors are the small and wearable device that records the rhythm of heart. It is utilized to determine or detect irregular heartbeats (arrhythmias) risk. Holter monitors test is usually done if a traditional electrocardiogram is unable to provide sufficient details about the condition of the heart. These monitors can spot irregular heart rhythms that may be missed by ECG. Holter monitoring is non-invasive and painless. The monitor is usually worn for 1 to 2 days in which all the heartbeats are recorded by the device. The sensors and the wires are easy to hide under clothing. The device can be attached to a strap or worn on a belt.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drives the market's growth. For instance, in January 26, 2022, Royal Philips, a health technology company announced about introducing the first at-home, full-service, 12-lead electrocardiogram (ECG) solution that can be utilized in decentralized clinical trials. This clinical-grade solution is the highly advanced patient-centric ECG included within the cardiac monitoring portfolio of Philips, site-based ECGs with leading cloud-based data collection and evaluation services of Philips.

Geographical Analysis

North America holds the largest market share in the global cardiac arrhythmia monitoring devices market.

North America dominates the global cardiac arrhythmia monitoring devices market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively moderate pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of cardiac arrhythmia monitoring devices such as pacemaker, event monitors, ECG devices or holter monitors, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the cardiac arrhythmia monitoring devices market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in February 10, 2021, CardiacSense, a digital health company involved in developing a medical grade watch announced about receiving the CE Mark for its medical grade smart watch device's marketing & sales in the European Union. The certified indications include Heart Rate Variability (HRV) monitoring and detection of Atrial Fibrillation (A-Fib) with spot Electrocardiogram (ECG) and continuous Photoplethysmography (PPG).

Competitive Landscape

The cardiac arrhythmia monitoring devices market is moderately competitive with local and global companies' presence. Philips Healthcare, GE Healthcare, Medtronic PLC, Cardiac Sense, BIOTRONIK, iRhythm Technologies, Inc., Preventice Solutions (Boston Scientific Corporation), Medi-Lynx Cardiac Monitoring, LLC., ACS Diagnostics, Abbott and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in January 21, 2021, Boston Scientific announced about entering into a definitive acquisition agreement with Preventice Solutions, Inc., a company offering a whole portfolio of mobile cardiac health solutions and services, including ambulatory cardiac monitors such as long and short-term Holter monitor, mobile cardiac telemetry and cardiac event monitors.

GE Healthcare

Overview: GE Healthcare is a subsidiary of American multinational conglomerate General Electric Company. The company manufactures and distributes diagnostic imaging agents and radiopharmaceuticals for imaging modalities used in medical imaging procedures.

Product Portfolio:

CARESCAPE B850 monitor: It incorporates technologically advanced features including smart lead fail and four lead arrhythmia analysis facilitated by EK-Pro algorithm of GE Healthcare. The monitor also provide a broad range of basic or advanced clinical parameters such as regional oximetry (rSO2), plethysmography variability index (PVI), Perfusion Index (PI) and total hemoglobin (SpHb).

Key Development: In July 16, 2022, GE Healthcare announced about introducing portrait mobile continuous wireless wearable sensors patient monitoring solution for supporting clinicians in detecting early patient deterioration.

The global cardiac arrhythmia monitoring devices market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing development of smart cardiac monitors
      • 4.1.1.2. Rising demand for telecardiology
    • 4.1.2. Restraints:
      • 4.1.2.1. Uncertain reimbursement policies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Holter Monitor *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 7.3. ECG Devices
  • 7.4. Mobile Cardiac Telemetry
  • 7.5. Cardiac Event Monitors
  • 7.6. Implantable Loop Recorders
  • 7.7. Patch Monitor
  • 7.8. Pacemaker
  • 7.9. Cardioverter-Defibrillator

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Atrial Fibrillation *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 8.3. Bradycardia
  • 8.4. Atrial Tachycardia
  • 8.5. Ventricular Tachycardia
  • 8.6. Ventricular Fibrillation
  • 8.7. Premature Contraction
  • 8.8. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Diagnostic Centers
  • 9.5. Specialty Clinics

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Philips Healthcare *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GE Healthcare
  • 12.3. Medtronic PLC
  • 12.4. Cardiac Sense
  • 12.5. BIOTRONIK
  • 12.6. iRhythm Technologies, Inc.
  • 12.7. Preventice Solutions (Boston Scientific Corporation)
  • 12.8. Medi-Lynx Cardiac Monitoring LLC.
  • 12.9. ACS Diagnostics
  • 12.10. Abbott

LIST NOT EXHAUSTIVE

13. Global Cardiac Arrhythmia Monitoring Devices Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Medications
  • 13.3. Contact Us